Rexahn Pharmaceuticals, Inc. (RNN) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. trimmed its stake in Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) by 83.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 841,146 shares of the company’s stock after selling 4,380,927 shares during the period. Vanguard Group Inc. owned 3.31% of Rexahn Pharmaceuticals worth $2,405,000 as of its most recent SEC filing.

Separately, Renaissance Technologies LLC lifted its position in shares of Rexahn Pharmaceuticals by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock worth $2,937,000 after purchasing an additional 862,000 shares during the period.

A number of brokerages recently issued reports on RNN. Zacks Investment Research raised shares of Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research report on Friday, November 10th. HC Wainwright reissued a “buy” rating and set a $19.50 price target on shares of Rexahn Pharmaceuticals in a research report on Monday, November 6th. ValuEngine raised shares of Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 2nd. Finally, Seaport Global Securities reissued a “buy” rating and set a $13.00 price target on shares of Rexahn Pharmaceuticals in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $13.65.

Shares of Rexahn Pharmaceuticals, Inc. (RNN) traded down $0.03 during midday trading on Thursday, reaching $2.05. 160,800 shares of the company were exchanged, compared to its average volume of 445,575. Rexahn Pharmaceuticals, Inc. has a one year low of $1.30 and a one year high of $7.10.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at

Rexahn Pharmaceuticals Profile

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Want to see what other hedge funds are holding RNN? Visit to get the latest 13F filings and insider trades for Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN).

Institutional Ownership by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply